Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer

E. Dubaere, M. Goffaux, M. Wanet, Benoît Bihin, Céline Gheldof, Anne-Sophie Demoulin, A. Bolly, F. Bustin, F. Duplaquet, P.E. Baugnee, M. Gustin, V. Hers, F. Maisin, Éric Marchand, Sebehat Ocak, Lionel Pirard, O. Vancutsem, E. Van Neck, G. Vandermoten, L. Zaharia & 1 others V. Remouchamps

Research output: Contribution to journalArticle

2 Downloads (Pure)

Abstract

Background
To evaluate the outcome of patients treated with stereotactic ablative body radiotherapy (SABR) with curative intent for stage I non-small cell lung cancer (NSCLC) with regard to local, regional and distant tumor control, disease-free survival (DFS), overall survival (OS) and toxicity.

Methods
Data of 300 patients treated with SABR for NSCLC cancer for the period of November 2007 to June 2016 were retrospectively analyzed. Of which, 189 patients had single primary lung lesion and were included in the study. The prescribed dose for the tumor was 48 Gy, given in 12 Gy × 4 fractions for all patients. In 2010, an improved protocol was established in advanced technology for the planning CT, dose calculation and imaging. Cumulative incidence function (CIF) of local, regional, distant or any recurrences were computed using competing risk analysis with death as a competing event. Survivals (DFS and OS) were estimated using the Kaplan-Meier method and Cox proportional regression was used for comparisons. Toxicities were graded according to the common terminology criteria for adverse events version 4.0 (CTCAE v.4).

Results
Diagnosis was histologically confirmed in 42% of the patients (N = 80). At 1, 2 and 4 years, the cumulative incidence function (CIF) of local relapses were 8% [4–13%], 15% [10–21%] and 18% [12–25%], the CIF of regional relapses were 4% [2–8%], 10% [6–16%] and 12% [8–19%], the CIF of distant relapses were 9% [5–14%], 15% [11–22%] and 20% [15–28%] and the CIF of any relapses were 14% [10–20%], 28% [22–36%], 34% [27–43%], respectively. After 1, 2 and 4 years, the OS rates were 83% [95% CI: 78–89%] (N = 128), 65% [95% CI: 57–73%] (N = 78) and 37% [95% CI: 29–47%] (N = 53), respectively. The median survival time was 37 months. The DFS after 1, 2 and 4 years reached 75% [95% CI: 68–81%] (N = 114), 49% [95% CI: 42–58%] (N = 60) and 31% [95% CI: 24–41%] (N = 41), respectively. No grade 4 or 5 toxicity was observed.

Conclusions
We observed a long-term local control and survival after SABR for peripheral stage I NSCLC in this large series of patients with the expected low toxicity.
Original languageEnglish
Article number19
Pages (from-to)1
Number of pages8
JournalBMC Cancer
Volume19
DOIs
Publication statusPublished - 2019

Fingerprint

Radiosurgery
Non-Small Cell Lung Carcinoma
Recurrence
Survival
Incidence
Disease-Free Survival
Neoplasms
Terminology
Survival Rate
Technology
Lung

Cite this

Dubaere, E. ; Goffaux, M. ; Wanet, M. ; Bihin, Benoît ; Gheldof, Céline ; Demoulin, Anne-Sophie ; Bolly, A. ; Bustin, F. ; Duplaquet, F. ; Baugnee, P.E. ; Gustin, M. ; Hers, V. ; Maisin, F. ; Marchand, Éric ; Ocak, Sebehat ; Pirard, Lionel ; Vancutsem, O. ; Van Neck, E. ; Vandermoten, G. ; Zaharia, L. ; Remouchamps, V. / Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer. In: BMC Cancer. 2019 ; Vol. 19. pp. 1.
@article{5c34379023f04dc5a435bc910f647421,
title = "Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer",
abstract = "BackgroundTo evaluate the outcome of patients treated with stereotactic ablative body radiotherapy (SABR) with curative intent for stage I non-small cell lung cancer (NSCLC) with regard to local, regional and distant tumor control, disease-free survival (DFS), overall survival (OS) and toxicity.MethodsData of 300 patients treated with SABR for NSCLC cancer for the period of November 2007 to June 2016 were retrospectively analyzed. Of which, 189 patients had single primary lung lesion and were included in the study. The prescribed dose for the tumor was 48 Gy, given in 12 Gy × 4 fractions for all patients. In 2010, an improved protocol was established in advanced technology for the planning CT, dose calculation and imaging. Cumulative incidence function (CIF) of local, regional, distant or any recurrences were computed using competing risk analysis with death as a competing event. Survivals (DFS and OS) were estimated using the Kaplan-Meier method and Cox proportional regression was used for comparisons. Toxicities were graded according to the common terminology criteria for adverse events version 4.0 (CTCAE v.4).ResultsDiagnosis was histologically confirmed in 42{\%} of the patients (N = 80). At 1, 2 and 4 years, the cumulative incidence function (CIF) of local relapses were 8{\%} [4–13{\%}], 15{\%} [10–21{\%}] and 18{\%} [12–25{\%}], the CIF of regional relapses were 4{\%} [2–8{\%}], 10{\%} [6–16{\%}] and 12{\%} [8–19{\%}], the CIF of distant relapses were 9{\%} [5–14{\%}], 15{\%} [11–22{\%}] and 20{\%} [15–28{\%}] and the CIF of any relapses were 14{\%} [10–20{\%}], 28{\%} [22–36{\%}], 34{\%} [27–43{\%}], respectively. After 1, 2 and 4 years, the OS rates were 83{\%} [95{\%} CI: 78–89{\%}] (N = 128), 65{\%} [95{\%} CI: 57–73{\%}] (N = 78) and 37{\%} [95{\%} CI: 29–47{\%}] (N = 53), respectively. The median survival time was 37 months. The DFS after 1, 2 and 4 years reached 75{\%} [95{\%} CI: 68–81{\%}] (N = 114), 49{\%} [95{\%} CI: 42–58{\%}] (N = 60) and 31{\%} [95{\%} CI: 24–41{\%}] (N = 41), respectively. No grade 4 or 5 toxicity was observed.ConclusionsWe observed a long-term local control and survival after SABR for peripheral stage I NSCLC in this large series of patients with the expected low toxicity.",
author = "E. Dubaere and M. Goffaux and M. Wanet and Beno{\^i}t Bihin and C{\'e}line Gheldof and Anne-Sophie Demoulin and A. Bolly and F. Bustin and F. Duplaquet and P.E. Baugnee and M. Gustin and V. Hers and F. Maisin and {\'E}ric Marchand and Sebehat Ocak and Lionel Pirard and O. Vancutsem and {Van Neck}, E. and G. Vandermoten and L. Zaharia and V. Remouchamps",
year = "2019",
doi = "https://doi.org/10.1186/s12885-019-5863-2",
language = "English",
volume = "19",
pages = "1",
journal = "BMC Cancer",
issn = "1471-2407",
publisher = "BioMed Central",

}

Dubaere, E, Goffaux, M, Wanet, M, Bihin, B, Gheldof, C, Demoulin, A-S, Bolly, A, Bustin, F, Duplaquet, F, Baugnee, PE, Gustin, M, Hers, V, Maisin, F, Marchand, É, Ocak, S, Pirard, L, Vancutsem, O, Van Neck, E, Vandermoten, G, Zaharia, L & Remouchamps, V 2019, 'Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer', BMC Cancer, vol. 19, 19, pp. 1. https://doi.org/10.1186/s12885-019-5863-2

Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer. / Dubaere, E.; Goffaux, M.; Wanet, M.; Bihin, Benoît; Gheldof, Céline; Demoulin, Anne-Sophie; Bolly, A.; Bustin, F.; Duplaquet, F.; Baugnee, P.E.; Gustin, M.; Hers, V.; Maisin, F.; Marchand, Éric; Ocak, Sebehat; Pirard, Lionel; Vancutsem, O.; Van Neck, E.; Vandermoten, G.; Zaharia, L.; Remouchamps, V.

In: BMC Cancer, Vol. 19, 19, 2019, p. 1.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer

AU - Dubaere, E.

AU - Goffaux, M.

AU - Wanet, M.

AU - Bihin, Benoît

AU - Gheldof, Céline

AU - Demoulin, Anne-Sophie

AU - Bolly, A.

AU - Bustin, F.

AU - Duplaquet, F.

AU - Baugnee, P.E.

AU - Gustin, M.

AU - Hers, V.

AU - Maisin, F.

AU - Marchand, Éric

AU - Ocak, Sebehat

AU - Pirard, Lionel

AU - Vancutsem, O.

AU - Van Neck, E.

AU - Vandermoten, G.

AU - Zaharia, L.

AU - Remouchamps, V.

PY - 2019

Y1 - 2019

N2 - BackgroundTo evaluate the outcome of patients treated with stereotactic ablative body radiotherapy (SABR) with curative intent for stage I non-small cell lung cancer (NSCLC) with regard to local, regional and distant tumor control, disease-free survival (DFS), overall survival (OS) and toxicity.MethodsData of 300 patients treated with SABR for NSCLC cancer for the period of November 2007 to June 2016 were retrospectively analyzed. Of which, 189 patients had single primary lung lesion and were included in the study. The prescribed dose for the tumor was 48 Gy, given in 12 Gy × 4 fractions for all patients. In 2010, an improved protocol was established in advanced technology for the planning CT, dose calculation and imaging. Cumulative incidence function (CIF) of local, regional, distant or any recurrences were computed using competing risk analysis with death as a competing event. Survivals (DFS and OS) were estimated using the Kaplan-Meier method and Cox proportional regression was used for comparisons. Toxicities were graded according to the common terminology criteria for adverse events version 4.0 (CTCAE v.4).ResultsDiagnosis was histologically confirmed in 42% of the patients (N = 80). At 1, 2 and 4 years, the cumulative incidence function (CIF) of local relapses were 8% [4–13%], 15% [10–21%] and 18% [12–25%], the CIF of regional relapses were 4% [2–8%], 10% [6–16%] and 12% [8–19%], the CIF of distant relapses were 9% [5–14%], 15% [11–22%] and 20% [15–28%] and the CIF of any relapses were 14% [10–20%], 28% [22–36%], 34% [27–43%], respectively. After 1, 2 and 4 years, the OS rates were 83% [95% CI: 78–89%] (N = 128), 65% [95% CI: 57–73%] (N = 78) and 37% [95% CI: 29–47%] (N = 53), respectively. The median survival time was 37 months. The DFS after 1, 2 and 4 years reached 75% [95% CI: 68–81%] (N = 114), 49% [95% CI: 42–58%] (N = 60) and 31% [95% CI: 24–41%] (N = 41), respectively. No grade 4 or 5 toxicity was observed.ConclusionsWe observed a long-term local control and survival after SABR for peripheral stage I NSCLC in this large series of patients with the expected low toxicity.

AB - BackgroundTo evaluate the outcome of patients treated with stereotactic ablative body radiotherapy (SABR) with curative intent for stage I non-small cell lung cancer (NSCLC) with regard to local, regional and distant tumor control, disease-free survival (DFS), overall survival (OS) and toxicity.MethodsData of 300 patients treated with SABR for NSCLC cancer for the period of November 2007 to June 2016 were retrospectively analyzed. Of which, 189 patients had single primary lung lesion and were included in the study. The prescribed dose for the tumor was 48 Gy, given in 12 Gy × 4 fractions for all patients. In 2010, an improved protocol was established in advanced technology for the planning CT, dose calculation and imaging. Cumulative incidence function (CIF) of local, regional, distant or any recurrences were computed using competing risk analysis with death as a competing event. Survivals (DFS and OS) were estimated using the Kaplan-Meier method and Cox proportional regression was used for comparisons. Toxicities were graded according to the common terminology criteria for adverse events version 4.0 (CTCAE v.4).ResultsDiagnosis was histologically confirmed in 42% of the patients (N = 80). At 1, 2 and 4 years, the cumulative incidence function (CIF) of local relapses were 8% [4–13%], 15% [10–21%] and 18% [12–25%], the CIF of regional relapses were 4% [2–8%], 10% [6–16%] and 12% [8–19%], the CIF of distant relapses were 9% [5–14%], 15% [11–22%] and 20% [15–28%] and the CIF of any relapses were 14% [10–20%], 28% [22–36%], 34% [27–43%], respectively. After 1, 2 and 4 years, the OS rates were 83% [95% CI: 78–89%] (N = 128), 65% [95% CI: 57–73%] (N = 78) and 37% [95% CI: 29–47%] (N = 53), respectively. The median survival time was 37 months. The DFS after 1, 2 and 4 years reached 75% [95% CI: 68–81%] (N = 114), 49% [95% CI: 42–58%] (N = 60) and 31% [95% CI: 24–41%] (N = 41), respectively. No grade 4 or 5 toxicity was observed.ConclusionsWe observed a long-term local control and survival after SABR for peripheral stage I NSCLC in this large series of patients with the expected low toxicity.

U2 - https://doi.org/10.1186/s12885-019-5863-2

DO - https://doi.org/10.1186/s12885-019-5863-2

M3 - Article

VL - 19

SP - 1

JO - BMC Cancer

JF - BMC Cancer

SN - 1471-2407

M1 - 19

ER -